Through the results of pancancer analysis and clinical data, we found that NR2F6 was significantly related to NB prognosis and metastasis, suggesting that targeting NR2F6 may be one of the potential strategies for NB treatment. This evidence concerns the gene NR2F6 and neuroblastoma.